Online Course
on demand
31
Mar
2023
01
Apr
2023
Adverse Events Management and Interstitial Lung Disease (ILD) Detection Online Course
Chairs
Alfredo Addeo, CH - Aleksandra Filipovic, UK
 
Date
31 March - 01 April 2023

Background
Interstitial Lung Disease (ILD) is an issue for many cancers and cancer treatments. With the development of immunotherapies, it has become a focus of attention, but it is an historical issue related to radiation, busulfan and bleomycin.
Many treatments in various disease areas have ILD as a potential toxicity. Early diagnosis is crucial to avoid irreversible damage or even death of the patient.
 
Following the Task Force (held on April 25), the results of which have been summarised in a scientific article published on the Cancerworld magazine, the ILD Project foresaw the following steps:
- Five Podcasts, consisting of short contributions on the topic by Task Force experts, will be developed. The podcasts will be free of charge and accessible to the audience by registering on SPCC's OncoCorner e-learning platform.
- three Educational Webinars free of charge and accessible to the audience by registering on SPCC's OncoCorner e-learning platform.
 
The online course, final step of the project, will summarise the main topics from the previous Task Force and webinars, available via OncoCorner.
 
Course Goals
The aim of this project is to expand awareness and knowledge among HPCs about:
•  The frequency of ILD with various oncological treatments;
•  Patients at major risk and methods if any to avoid ILD; 
•  The appropriate methods to diagnose ILD early, with or without sophisticated radiological methods;
•  Treatment of ILD and possible reinstatement of the oncological drug.
 
Target Group
HCP’s - Medical oncologists – Haematologists - Radiation oncologists – Pulmonologists - Radiologists
 
Course Format
The course will be held online with the participation of world-renowned experts, some of them already involved in the Task Force, podcasts and webinars.
It will be free of charge and can be accessed by registering on SPCC's OncoCorner e-learning platform. The material will remain available on-demand.

Course Content
The event will consist of 2 consecutive days of live sessions.

Continuing Medical Education accreditation
Application for CME accreditation has been submitted to the Accreditation Council of Oncology in Europe (ACOE).
The programme was recognised as being of high quality from both a scientific and didactic point of view and was awarded 4 CME credits.
Participants will be issued a certificate of attendance (minimum attendance: 75% of the entire course). An online evaluation questionnaire and learning assessment test will need to be completed in order to get the certificate that will be issued by email.
 
Acknowledgements
Sharing Progress in Cancer Care wishes to express its appreciation to AstraZeneca and Daiichi Sankyo for their unrestricted educational grants.
31/03/2023 15:30 CEST

DAY 1

31/03/2023 15:30 CEST

Welcome and introduction

Chair: Addeo Alfredo, CH
Chair: Filipovic Aleksandra, UK
31/03/2023 15:40 CEST

ILD and cancer drugs

Expert: Filipovic Aleksandra, UK
31/03/2023 16:00 CEST

Practical approach to diagnose interstitial lung disease (ILD): tips from the pneumologist to the oncologist

Expert: Bendstrup Elisabeth, DK
31/03/2023 16:20 CEST

Practical approach to diagnose ILD: tips from the radiologist to the oncologist

Expert: Schaefer-Prokop Cornelia, NL
31/03/2023 16:40 CEST

ILDs in GI malignancies treated with novel anti-HER2 ADC

Expert: Wainberg Zev, US
31/03/2023 17:00 CEST

Educational session discussion and Q&A

Chair: Addeo Alfredo, CH
Chair: Filipovic Aleksandra, UK
Expert: Bendstrup Elisabeth, DK
Expert: Schaefer-Prokop Cornelia, NL
Expert: Wainberg Zev, US
31/03/2023 17:25 CEST

Closure

Chair: Addeo Alfredo, CH
Chair: Filipovic Aleksandra, UK
01/04/2023 14:30 CEST

DAY 2

01/04/2023 14:30 CEST

Welcome and introduction

Chair: Addeo Alfredo, CH
Chair: Filipovic Aleksandra, UK
01/04/2023 14:40 CEST

Summary of Webinar 2: - Interstitial lung disease (ILD) and monoclonal antibodies, mTOR inhibitors and CDK4/6 inhibitors: ADCs or T-DXd and other ADCs

Expert: Dieras Veronique, FR
01/04/2023 15:00 CEST

Interstitial lung disease practical management: can you restart the drug if it was giving benefit?

Expert: Marra Antonio, IT
01/04/2023 15:20 CEST

ILDs seen with checkpoint inhibitors

Expert: Bockorny Bruno, US
01/04/2023 15:40 CEST

ILD and Radiation Oncology

Expert: Senan Suresh , NL
01/04/2023 16:00 CEST

Educational session discussion and Q&A

Chair: Addeo Alfredo, CH
Chair: Filipovic Aleksandra, UK
Expert: Bockorny Bruno, US
Expert: Dieras Veronique, FR
Expert: Marra Antonio, IT
Expert: Senan Suresh , NL
01/04/2023 16:25 CEST

Closure

Chair: Addeo Alfredo, CH
Chair: Filipovic Aleksandra, UK
Addeo Alfredo

Oncology Division, University Hospital Geneva, Geneve, Switzerland
Bendstrup Elisabeth

Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark
Bockorny Bruno

Clinical Director, Phase 1 Oncology Program Beth at Israel Deaconess Medical Center, Boston, USA
Dieras Veronique

Senior Medical Oncologist at Centre Eugène-Marquis, Rennes, France
Filipovic Aleksandra

Imperial College London, London, United Kingdom
Marra Antonio

Attending Physician, Early Drug Development for Innovative Therapies at European Institute of Oncology IRCSS, Milan, Italy
Schaefer-Prokop Cornelia

Radiologist at Meander Medical Centre, Amersfoort, The Netherlands
Senan Suresh

Amsterdam University Medical Centers, VUmc location, Amsterdam, The Netherlands
Wainberg Zev

Professor of Medicine at UCLA and co-director of the UCLA GI Oncology Program, Los Angeles, USA
This material is part of Educational Project:
2022 - Adverse Events Management and Interstitial Lung Disease (ILD) Detection Project